Product details
AOD9604 is a modified analog of the C-terminal 176-191 fragment of human growth hormone, developed at Monash University in Australia as a lipolytic / anti-obesity research and clinical-development candidate. The molecule consists of the native HGH(176-191) sequence with an additional N-terminal tyrosine residue added to support iodination for tracking studies during preclinical development. AOD9604 retains the lipolytic activity associated with the HGH C-terminal region (the segment hypothesized to drive fat-cell lipolysis through a non-GH-receptor mechanism) while lacking the broader anabolic effects mediated by the full-length HGH molecule's central regions. The molecule advanced through Phase 2 clinical development for obesity but did not achieve regulatory approval; it has since transitioned to research-use and dietary-supplement markets in some jurisdictions.
Peptuno supplies lyophilized AOD9604 at ≥99.0% HPLC purity with batch-specific COA. The N-terminal tyrosine modification distinguishes AOD9604 from the unmodified HGH Fragment 176-191, buyers should be explicit about which they want at order placement. Three standard fill sizes (2, 5, 10 mg) cover typical research and compounding workflows.
FAQ
- Why is AOD9604 considered an 'anti-obesity drug candidate' rather than just a research peptide?
- AOD9604 was developed at Monash University in Australia and advanced through Phase 2b clinical trials for obesity as a registered drug-development program. The trials produced modest weight-loss signals (smaller than what GLP-1 agonists have since demonstrated), and the program did not achieve regulatory approval as a finished drug. Following discontinuation of the obesity-drug program, AOD9604 transitioned to research-use and to dietary-supplement markets in some jurisdictions, where it is marketed under various brand names. The 'anti-obesity drug candidate' framing reflects the molecule's clinical-development history; buyers should not assume the molecule is an approved drug.
- Is AOD9604 a GH analog, and does it activate the GH receptor?
- AOD9604 is derived from the C-terminal region of human GH (residues 176-191) but is not a GH receptor agonist, the GH-receptor-binding region of full-length GH is in the central portion of the protein, not the C-terminal fragment. AOD9604's lipolytic activity is hypothesized to act through a separate, non-GH-receptor mechanism. This is the key pharmacological distinction from full-length recombinant HGH: AOD9604 retains the lipolytic effects associated with the C-terminal region of GH but lacks the broader anabolic and IGF-1-stimulating effects mediated by the central GH-receptor-binding region. The downstream consequence is a substantially narrower pharmacological profile than HGH.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.
Related products
HGH Fragment 176-191
C-terminal fragment of human growth hormone (176–191)
Sermorelin
GHRH 1-29 fragment
Ipamorelin
Ghrelin / GHSR pathway GH-release peptide